Given the proven efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in reducing the risk of cardiovascular events and chronic kidney disease (CKD) progression, an SGLT2i is initially considered as a first-line treatment. Here, SLC5A2 is linked to chronic kidney disease.